Thursday, January 6, 2011

Clinical Trial Information: AEG35156

Trial Information: 51 patients are being recruited for a Phase I/II trial of the XIAP antisense AEG35156 in indolent lymphomas (including follicular lymphoma) and chronic lymphocytic leukemia (CLL). Patients must meet criteria for third-line treatment (or beyond) to enter the trial.


Background Information: AEG35156 is an anti-XIAP antisense oligonucleotide which appears to make cancer cells more vulnerable to apoptosis (cell death), including cell death induced by other causes like additional chemotherapy agents. It is also being tested extensively for treatment of solid tumours, like liver cancer, breast cancer, and lung cancer.

Interest in AEG35156 as an anti-lymphoma agent follows the response of one non-Hodkgin's lymphoma patient during an early Phase I dose-ranging trial.

Canadian Locations: Calgary, AB (Tom Baker Cancer Center); Toronto, ON (Prince Margaret General Hospital); Montreal, QC (Jewish General Hospital)

For more information, see ClinicalTrials.gov.

No comments:

Post a Comment